---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-326778"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:30:59.815730+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics receives FDA approval for MYQORZO (aficamten) to treat symptomatic oHCM

## Summary
- FDA approved MYQORZO (aficamten) on Dec 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity, reducing contractility and LVOT obstruction.
- Available in 5 mg, 10 mg, 15 mg, and 20 mg tablets.
- Approval based on data showing improved functional capacity and symptoms in oHCM patients.

## SEC filing metadata
- accession: 0001193125-25-326778
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312525326778/0001193125-25-326778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312525326778/cytk-20251219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-326778
- JSON: https://secwatch.observer/filing/0001193125-25-326778.json
- Plain text: https://secwatch.observer/filing/0001193125-25-326778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.